The Society for Immunotherapy of Cancer (SITC) is a non-profit professional society founded in 1984 - originally as the Society for Biological Therapy, later the International Society for Biological Therapy of Cancer, and renamed the Society for Immunotherapy of Cancer to reflect its focus on cancer immunotherapy and a more global membership. It is headquartered in Milwaukee, Wisconsin, and reports more than 2,400 members spanning 22 medical specialties in 42 countries.

Unlike a commercial publisher, SITC runs a single-journal program. Its official publication is the Journal for ImmunoTherapy of Cancer (JITC), launched in 2013 and today published on SITC's behalf by BMJ Publishing Group. If you work in tumor immunology, immuno-oncology biomarkers, cellular therapy, or immunotherapy clinical trials, JITC is the venue this guide is about: what it publishes, what it costs, how peer review runs, and how to submit.

SITC publishes one journal, so the decision is less about picking a title and more about whether your manuscript fits JITC's scope and article types.

JITC is an open access, peer-reviewed online journal covering all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical application. Typical content includes:

• Original research - basic, translational, and clinical studies in immuno-oncology.
• Clinical trial reports - early- and late-phase immunotherapy trials and their correlative science.
• Reviews and position papers - state-of-the-field syntheses in tumor immunology.
• SITC clinical practice guidelines - the society's consensus recommendations on immunotherapy for specific tumor types and on managing immune-related adverse events.
• Annual Meeting abstracts - abstracts accepted for the SITC Annual Meeting are published as a JITC supplement.

JITC is indexed in PubMed and PMC, Scopus, Web of Science (Science Citation Index Expanded), and DOAJ. Its Journal Impact Factor has sat in the roughly 10-11 range in recent JCR releases; check the current JCR for the exact figure, since journal-level metrics move every year.

JITC is fully open access - there is no subscription route and no paywalled tier. Articles are published under a Creative Commons licence, with CC BY the standard option for most authors and CC BY-NC / CC BY-NC-ND available in some circumstances. Because SITC is the owning society and BMJ is the publisher, the fees and waiver machinery are BMJ's.

APCs are revised periodically and currency conversion moves, so confirm the current figure on the JITC author pages before you submit rather than budgeting from a secondary source.

JITC uses anonymized external peer review coordinated by an academic editorial board drawn largely from the SITC community. Reviewers are asked to assess immunological rigor as well as clinical relevance, which in practice means correlative and mechanistic data are scrutinized closely even in clinical submissions. Decisions on trial reports commonly hinge on whether the immune-correlate analyses support the clinical claims.

Turnaround varies by article type and reviewer availability; JITC's editorial office publishes current performance data, so check the journal's author pages rather than relying on community estimates.

1. Check scope. Read a recent issue and JITC's aims and scope; immuno-oncology relevance is the gate.
2. Pick the article type. Original research, review, position paper, clinical trial report, or case series each have their own length and structure requirements.
3. Prepare the manuscript. Follow BMJ house style; use Vancouver-style numbered references and the reporting checklist that matches your study design (CONSORT, STROBE, ARRIVE, PRISMA).
4. Register data and trials. Clinical trials must be prospectively registered; JITC expects a data availability statement.
5. Submit through the online system. JITC uses BMJ's ScholarOne-based submission platform, reachable from the journal site.
6. Handle the APC after acceptance. Apply your SITC member discount, institutional Read & Publish agreement, or waiver at that stage.

JITC follows BMJ's editorial policies, which are built on COPE guidance: authorship and contributorship standards, competing-interest declarations, ethics approval statements, and COPE-aligned correction and retraction procedures. Competing-interest disclosure is taken seriously in immuno-oncology given the density of industry sponsorship - expect to itemize consultancies, advisory roles, and trial funding. BMJ is also an OASPA member, and JITC content is deposited in PMC.